Global Targeted Radiopharmaceuticals Market Growth 2025-2031
Description
The global Targeted Radiopharmaceuticals market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Targeted radiopharmaceuticals are a type of medicinal product that combines a biologically active molecule (known as a ligand or targeting agent) with a radioactive isotope (radionuclide). These radiopharmaceuticals are designed to deliver radiation specifically to certain cells, tissues, or organs in the body, with the goal of achieving precise and localized treatment or imaging.
The concept of targeted radiopharmaceuticals is based on the idea of using the biological specificity of the ligand to selectively bind to receptors or antigens present on the target cells. Once the ligand has bound to its target, the radioactive component emits radiation that can be used for therapeutic purposes or imaging.There are two main categories of targeted radiopharmaceuticals: targeted therapeutic radiopharmaceuticals and targeted diagnostic radiopharmaceuticals.
Targeted radiopharmaceuticals offer several advantages over traditional treatments or imaging agents, including increased specificity, reduced damage to healthy tissues, and the potential for personalized medicine approaches based on the patient"s specific disease characteristics. However, the development and use of targeted radiopharmaceuticals require careful consideration of the ligand"s biological properties, radionuclide characteristics, and safety profiles to ensure effective and safe medical applications.
The radiopharmaceuticals market had been experiencing steady growth and significant interest due to the increasing use of nuclear medicine procedures for diagnostic and therapeutic purposes. Radiopharmaceuticals are essential tools in nuclear medicine, and they play a crucial role in diagnosing various diseases, such as cancer, cardiovascular conditions, and neurological disorders.
The radiopharmaceuticals market had been growing steadily over the years. Factors contributing to this growth include advancements in radiopharmaceutical development, rising prevalence of cancer and cardiovascular diseases, and an aging population that drives the demand for diagnostic procedures.
LP Information, Inc. (LPI) ' newest research report, the “Targeted Radiopharmaceuticals Industry Forecast” looks at past sales and reviews total world Targeted Radiopharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Radiopharmaceuticals sales for 2025 through 2031. With Targeted Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Radiopharmaceuticals industry.
This Insight Report provides a comprehensive analysis of the global Targeted Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Radiopharmaceuticals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Radiopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Radiopharmaceuticals.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Targeted Therapeutic Radiopharmaceuticals
Targeted Diagnostic Radiopharmaceuticals
Segmentation by Application:
Targeted Therapy
Targeted Diagnosis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novartis
Bayer
Lantheus
Institute for Radioelements (IRE)
Radiomedix
Curium Pharma
Clarity Pharmaceuticals
ROTOP
Ratio Therapeutics
Fusion Pharmaceuticals
Perspective Therapeutics
RayzeBio
Alpha-9 Theranostics
Radiopharm Theranostics
Telix Pharmaceuticals
Ariceum Therapeutics
Aktis Oncology
Navidea Biopharmaceuticals
Nucleus RadioPharma
SmartNuclide Biopharma
TetraKit Technologies
Key Questions Addressed in this Report
What is the 10-year outlook for the global Targeted Radiopharmaceuticals market?
What factors are driving Targeted Radiopharmaceuticals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Radiopharmaceuticals market opportunities vary by end market size?
How does Targeted Radiopharmaceuticals break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Targeted radiopharmaceuticals are a type of medicinal product that combines a biologically active molecule (known as a ligand or targeting agent) with a radioactive isotope (radionuclide). These radiopharmaceuticals are designed to deliver radiation specifically to certain cells, tissues, or organs in the body, with the goal of achieving precise and localized treatment or imaging.
The concept of targeted radiopharmaceuticals is based on the idea of using the biological specificity of the ligand to selectively bind to receptors or antigens present on the target cells. Once the ligand has bound to its target, the radioactive component emits radiation that can be used for therapeutic purposes or imaging.There are two main categories of targeted radiopharmaceuticals: targeted therapeutic radiopharmaceuticals and targeted diagnostic radiopharmaceuticals.
Targeted radiopharmaceuticals offer several advantages over traditional treatments or imaging agents, including increased specificity, reduced damage to healthy tissues, and the potential for personalized medicine approaches based on the patient"s specific disease characteristics. However, the development and use of targeted radiopharmaceuticals require careful consideration of the ligand"s biological properties, radionuclide characteristics, and safety profiles to ensure effective and safe medical applications.
The radiopharmaceuticals market had been experiencing steady growth and significant interest due to the increasing use of nuclear medicine procedures for diagnostic and therapeutic purposes. Radiopharmaceuticals are essential tools in nuclear medicine, and they play a crucial role in diagnosing various diseases, such as cancer, cardiovascular conditions, and neurological disorders.
The radiopharmaceuticals market had been growing steadily over the years. Factors contributing to this growth include advancements in radiopharmaceutical development, rising prevalence of cancer and cardiovascular diseases, and an aging population that drives the demand for diagnostic procedures.
LP Information, Inc. (LPI) ' newest research report, the “Targeted Radiopharmaceuticals Industry Forecast” looks at past sales and reviews total world Targeted Radiopharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Targeted Radiopharmaceuticals sales for 2025 through 2031. With Targeted Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Radiopharmaceuticals industry.
This Insight Report provides a comprehensive analysis of the global Targeted Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Radiopharmaceuticals market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Radiopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Radiopharmaceuticals.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Targeted Therapeutic Radiopharmaceuticals
Targeted Diagnostic Radiopharmaceuticals
Segmentation by Application:
Targeted Therapy
Targeted Diagnosis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novartis
Bayer
Lantheus
Institute for Radioelements (IRE)
Radiomedix
Curium Pharma
Clarity Pharmaceuticals
ROTOP
Ratio Therapeutics
Fusion Pharmaceuticals
Perspective Therapeutics
RayzeBio
Alpha-9 Theranostics
Radiopharm Theranostics
Telix Pharmaceuticals
Ariceum Therapeutics
Aktis Oncology
Navidea Biopharmaceuticals
Nucleus RadioPharma
SmartNuclide Biopharma
TetraKit Technologies
Key Questions Addressed in this Report
What is the 10-year outlook for the global Targeted Radiopharmaceuticals market?
What factors are driving Targeted Radiopharmaceuticals market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Radiopharmaceuticals market opportunities vary by end market size?
How does Targeted Radiopharmaceuticals break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
152 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Targeted Radiopharmaceuticals by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Targeted Radiopharmaceuticals by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
